But when we infused ex vivo activated TNFα-/- NK cells after allogeneic HSCT with IC, we observed improved tumor control compared to ex vivo activated TNFα+/+ NK cells (Figure 6C), suggesting TNFα may be contributing to CRS in a manner that attenuates the GVT potential of the infused NK cells. The gene discussed is TNF; the disease is congenital rubella syndrome.